TritonPoint Partners’s Halozyme HALO Stock Holding History

TritonPoint Partners’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,699	Closed	-$239K	–	368
2026 Q1	$239K	Sell	3,699 -674	-15%	-$47.5K	0.09%	180
2025 Q4	$294K	Buy	+4,373	New	+$294K	0.16%	124

Other funds holding HALO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

TritonPoint Partners's HALO Position: Q2 2026 in Review

TritonPoint Partners sold out of Halozyme (HALO) in Q2 2026, closing a stake of 3,699 shares — an estimated $239K sold.

TritonPoint Partners first reported a position in HALO in Q4 2025 and held it in 2 quarters. The position peaked at $294K in Q4 2025. 668 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

TritonPoint Partners reported no remaining Halozyme position as of Q2 2026 after selling out during the quarter.
TritonPoint Partners sold 3,699 Halozyme shares in Q2 2026, an estimated $239K.
TritonPoint Partners first reported a position in Halozyme in Q4 2025 and held it in 2 quarters.
TritonPoint Partners's Halozyme position peaked at $294K in Q4 2025.
668 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on TritonPoint Partners's 13F filing for Q2 2026, filed 13 Aug 2026.